The 4R-tauopathies—Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17)—share a common pathological feature: the accumulation of hyperphosphorylated four-repeat (4R) tau protein. Beyond tau pathology, these disorders exhibit prominent ferroptosis susceptibility, an iron-dependent form of regulated cell death driven by lipid peroxidation. This page examines the intersection of ferroptosis and lipid peroxidation mechanisms in 4R-tauopathies, providing a unified mechanistic framework that connects iron dysregulation, polyunsaturated fatty acid metabolism, glutathione peroxidase dysfunction, and oligodendrocyte vulnerability.
Ferroptosis was first formally described in 2012 as a distinct non-apoptotic cell death pathway characterized by iron-dependent accumulation of lipid hydroperoxides [@stockwell2012]. The 4R-tauopathies represent particularly vulnerable contexts for ferroptotic cell death due to the convergence of multiple risk factors: regional iron accumulation, impaired antioxidant defenses, high polyunsaturated fatty acid content in myelin sheaths, and oligodendrocyte susceptibility.
The 4R-tauopathies—Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17)—share a common pathological feature: the accumulation of hyperphosphorylated four-repeat (4R) tau protein. Beyond tau pathology, these disorders exhibit prominent ferroptosis susceptibility, an iron-dependent form of regulated cell death driven by lipid peroxidation. This page examines the intersection of ferroptosis and lipid peroxidation mechanisms in 4R-tauopathies, providing a unified mechanistic framework that connects iron dysregulation, polyunsaturated fatty acid metabolism, glutathione peroxidase dysfunction, and oligodendrocyte vulnerability.
Ferroptosis was first formally described in 2012 as a distinct non-apoptotic cell death pathway characterized by iron-dependent accumulation of lipid hydroperoxides [@stockwell2012]. The 4R-tauopathies represent particularly vulnerable contexts for ferroptotic cell death due to the convergence of multiple risk factors: regional iron accumulation, impaired antioxidant defenses, high polyunsaturated fatty acid content in myelin sheaths, and oligodendrocyte susceptibility.
Iron dysregulation is a hallmark of all 4R-tauopathies, creating the fundamental condition for ferroptosis initiation. Unlike Alzheimer's disease where iron accumulates primarily in cortical and hippocampal regions, or Parkinson's disease where the substantia nigra pars compacta is predominantly affected, 4R-tauopathies show distinctive regional iron patterns that correlate with their characteristic neuropathology [@berg2021][@bauer2022].
In PSP, the most extensively studied 4R-tauopathy, iron accumulation is most pronounced in the globus pallidus internus, substantia nigra pars reticulata, red nucleus, and subthalamic nucleus. This distribution corresponds precisely to the regions showing greatest neurodegeneration and tau pathology. Quantitative susceptibility mapping (QSM) MRI studies demonstrate that iron burden in these regions correlates with disease severity and progression rate [@valentini2023].
CBD shows iron accumulation in affected cortical regions (particularly Brodmann area 4), basal ganglia, and substantia nigra. The pattern correlates with astrocytic plaques and myelin breakdown. AGD demonstrates iron deposition in the anterior temporal lobe, hippocampal formation, and amygdala—regions characteristic of argyrophilic grain pathology. GGT shows prominent iron accumulation in subcortical white matter, reflecting the prominent oligodendroglial involvement in this disorder.
The divalent metal transporter 1 (DMT1) is upregulated across 4R-tauopathies, increasing cellular iron influx [@nichols2020]. This upregulation is particularly pronounced in PSP substantia nigra, where DMT1 expression increases 2-3 fold in neurons and glia. The mechanisms include:
Acyl-CoA synthetase long-chain family member 4 (ACSL4) plays a critical role in ferroptosis by activating polyunsaturated fatty acids (PUFAs) for incorporation into membrane phospholipids [@doll2017]. The resulting PUFA-phospholipids are highly susceptible to peroxidation, forming the substrate for ferroptotic cell death.
In 4R-tauopathies, ACSL4 expression is altered in ways that promote ferroptosis susceptibility:
| Disease | ACSL4 Expression | PUFA Metabolism | Vulnerability |
|---------|------------------|-----------------|---------------|
| PSP | Increased in SNc neurons | Accelerated | High |
| CBD | Variable by region | Dysregulated | Moderate-High |
| AGD | Moderate increase | Altered | Moderate |
| GGT | Elevated in oligodendrocytes | Enhanced | High |
| FTDP-17 | Mutation-dependent | Variable | Variable |
The enzymatic function of ACSL4 generates peroxidation-prone lipid species [@conrad2020]. Arachidonic acid (AA) and adrenic acid (AdA) are the primary substrates, and their incorporation into phosphatidylethanolamine (PE) creates membrane domains highly vulnerable to iron-catalyzed oxidation. In oligodendrocytes—particularly vulnerable in 4R-tauopathies due to their role in myelin maintenance—ACSL4 activity contributes to the exquisite sensitivity of these cells to ferroptotic death.
Peroxisomal dysfunction in 4R-tauopathies compounds ferroptosis vulnerability through multiple mechanisms [@baker2021][@kim2022]. Peroxisomes are essential for:
Glutathione peroxidase 4 (GPX4) is the central regulator preventing ferroptosis by reducing lipid hydroperoxides within membranes [@friedmann2014]. GPX4 requires glutathione (GSH) as its cofactor, creating a system vulnerable to both GSH depletion and GPX4 inactivation.
GPX4 expression is significantly compromised in all 4R-tauopathies:
System Xc- (SLC7A11/SLC3A2) is the cystine/glutamate antiporter that imports cystine for GSH synthesis. This system is downregulated in PSP and CBD:
Glutathione levels are significantly reduced in 4R-tauopathies [@park2023][@smith2022]:
The lipid peroxidation products generated in ferroptosis serve as both pathological mediators and biomarkers in 4R-tauopathies.
4-HNE is the most studied lipid peroxidation product in neurodegeneration. In 4R-tauopathies:
MDA is a widely used biomarker reflecting overall lipid peroxidation burden:
F2-isoprostanes are reliable in vivo markers of lipid peroxidation:
The following table summarizes ferroptosis and lipid peroxidation features across 4R-tauopathies:
| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| Iron Accumulation | Severe (GP, SN) | Moderate-High | Moderate | High (WM) | Variable |
| DMT1 Upregulation | +++ | ++ | + | ++ | ++ |
| Ferroportin Downregulation | -60% | -40% | -30% | -50% | Variable |
| GPX4 Reduction | 40-60% | 30-50% | 20-30% | 50-70% | Variable |
| GSH Depletion | 50% | 30-40% | 20-30% | 40-55% | Variable |
| ACSL4 Dysregulation | Increased | Variable | Moderate | Elevated | Variable |
| 4-HNE Adducts | +++ | ++ | + | +++ | ++ |
| Plasmalogen Loss | 35-50% | 40-55% | 15-25% | 45-60% | Variable |
| Oligodendrocyte Ferroptosis | Prominent | Present | Minor | Extensive | Variable |
| Ferroptosis Inhibitor Trials | Active | Planned | None | None | None |
PSP (Richardson Syndrome): The prototypical 4R-tauopathy shows the most severe ferroptosis susceptibility. Iron accumulation in the globus pallidus and substantia nigra creates the iron substrate. GSH depletion and GPX4 reduction compromise antioxidant defenses. The combination predicts high vulnerability to ferroptotic neuronal death.
CBD: Asymmetric cortical-subcortical involvement creates regional variations in ferroptosis susceptibility. Motor cortex and basal ganglia show the greatest vulnerability. Astrocytic involvement adds complexity, as astrocytes can both promote and protect against ferroptosis.
AGD: Predominant limbic system involvement correlates with temporal lobe ferroptosis patterns. The more indolent clinical course may reflect lower overall ferroptosis susceptibility compared to PSP and CBD.
GGT: White matter oligodendrocyte involvement creates unique ferroptosis vulnerability. Myelin's high lipid content makes it particularly susceptible to peroxidation. Plasmalogen deficiency compounds the vulnerability.
FTDP-17: MAPT mutation-specific patterns determine ferroptosis susceptibility. P301L mutations show prominent nigral iron accumulation similar to sporadic PSP.
Oligodendrocytes are particularly vulnerable to ferroptosis in 4R-tauopathies due to multiple converging factors:
This vulnerability explains the prominent white matter abnormalities seen in all 4R-tauopathies, particularly GGT.
Iron chelation addresses the primary trigger of ferroptosis [@devos2020][@dexter2022]:
| Agent | Target | Stage | Notes |
|-------|--------|-------|-------|
| Deferoxamine | Free iron | Phase 2 (PSP) | Subcutaneous; shows slowed progression |
| Deferiprone | Labile iron | Phase 2 | Oral; reduces brain iron on QSM |
| Clioquinol | Brain iron | Phase 2 | BBB-penetrant |
| VK-28 | Mitochondrial iron | Preclinical | Targeted delivery |
Direct ferroptosis inhibition targets the execution phase:
Restoring the primary ferroptosis defense system [@tardia2020]:
Targeting ACSL4 and related pathways [@lee2023]:
Given the multi-hit nature of ferroptosis susceptibility, combination therapies are likely most effective:
This mechanism intersects with multiple related pathways documented elsewhere on NeuroWiki:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving Ferroptosis and Lipid Peroxidation in 4R-Tauopathies discovered through SciDEX knowledge graph analysis: